Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.36% | -64.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.36% | -64.50% | |||
| Cost of Revenue | 21.12% | 18.32% | |||
| Gross Profit | -76.60% | -89.38% | |||
| SG&A Expenses | 23.06% | -13.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.43% | -5.34% | |||
| Operating Income | -39.86% | -526.92% | |||
| Income Before Tax | -19.92% | -2,846.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.92% | -2,846.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.92% | -2,846.72% | |||
| EBIT | -39.86% | -526.92% | |||
| EBITDA | -40.49% | -493.32% | |||
| EPS Basic | 20.59% | -1,879.93% | |||
| Normalized Basic EPS | -1.87% | -1,448.89% | |||
| EPS Diluted | 20.59% | -1,879.93% | |||
| Normalized Diluted EPS | -1.87% | -1,448.89% | |||
| Average Basic Shares Outstanding | 51.00% | 48.68% | |||
| Average Diluted Shares Outstanding | 51.00% | 48.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||